METTL1 tRNA Methyltransferase Inhibitors by STORM Therapeutics at ESMO
STORM Therapeutics Ltd., an advanced biotech firm dedicated to pioneering innovative small molecule treatments that interfere with RNA modifying enzymes for cancer and various other conditions, has disclosed that Group Leader Alexandra Sapetschnig will deliver a presentation outlining the findings and key takeaways from their research on the METTL1 tRNA methyltransferase project. This event is scheduled at the ESMO Congress focusing on Targeted Anticancer Therapies, which will be convened in Paris, France.
👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.
The talk, named "Inhibiting tRNA Methyltransferase METTL1 with Potent Small Molecules in Oncology," details new findings from STORM regarding the impact of chemically blocking a tRNA methyltransferase on cancer growth within animal test subjects.
Two separate classes of compounds have demonstrated the capability to inhibit METTL1 effectively with nanomolar potency in lab settings, showcasing distinct preference for this target over other RNA and protein methyltransferases. The mode of action for these inhibitors includes a decrease in methylation and the stability of certain tRNAs, which is a direct result of METTL1 activity being suppressed.
These inhibitors have also shown to hinder the proliferation and progression through the cell cycle in various cancerous cell lines, which is correlated with downregulated levels of proteins that regulate the cell cycle. When tested in live organisms, these METTL1 inhibitors successfully suppressed tumor development in mouse models that were both lacking an immune system and with functioning immunity.
Dr. Oliver Rausch, the head scientific expert at STORM Therapeutics, commented: "It's immensely gratifying to release these findings, which confirm that the strategic impairment of tRNA-related processes through blocking the novel enzyme METTL1 can lead to a reprogramming of cancer cells and a significant curtailment of cancer progression within living organisms.
These findings build upon our innovative research regarding METTL3, which was instrumental in identifying STC-15, a molecule now undergoing trials to treat advanced cancers. This reinforces the substantial promise in targeting RNA modifications in the genesis of novel oncological therapies. As STORM moves forward to refine and expand our proprietary drug discovery platform, these insights underscore the strides we are making in potentially revolutionizing cancer therapeutics."
👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!
According to the data provided by the Synapse Database, As of February 28, 2024, there are 4 investigational drugs for the METTL3 target, including 8 indications, 6 R&D institutions involved, with related clinical trials reaching 1, and as many as 315 patents.
STC-15 is an oral small molecule that inhibits METTL3, an RNA methyltransferase implicated in oncology and other diseases. Certain RNA methyltransferases are important regulators of RNA sensing and innate immune activation and represent novel immune-regulatory targets. Further research and clinical trials will be necessary to assess the efficacy and safety of STC-15 in treating the indicated conditions.
